Inside Innovation

Vancouver, Wash.-based biotech company AbSci raised an additional $65 million to help grow its synthetic biology platform. The company’s “Protein Printing” technology is used to

CBRE named Seattle’s life science industry one of the top in the nation, according to a recent report. Ranked ninth, Seattle brought in record venture

Fueled by unparalleled access to technology and a strong foundation of excellence in research, the life science industry in the Puget Sound region has grown

New census data shows that the number of Seattleites employed in STEM fields has more than doubled over the past decade, hitting almost 89,700 in

The University of Washington has moved up two spots to No. 8 in the latest ranking of Best Global Universities from U.S. News & World

Seattle-based Just – Evotec Biologics received funding from The Bill & Melinda Gates Foundation to seek out and work on new monoclonal antibody (mAb) drugs

Seattle-based biotech company HDT Bio raised $3 million in seed funding to support work on its COVID-19 vaccine candidate that uses a cutting-edge, replicating RNA

Seattle’s Fred Hutchinson Cancer Research Center announced that it is opening a new facility dedicated solely to testing treatments for people who have COVID-19, one

Despite an economic downturn, investment in Seattle’s biotech industry hasn’t slowed down this year. With Athira Pharma’s September IPO that raised $204 million, life science

Seattle-based Phase Genomics announced that it received two National Institutes of Health (NIH) grants totaling $3.9 million over three years. The funding will go towards

Sonoma Biosciences, which splits operations between South San Francisco and Seattle, received $40 million in financing to develop cell therapies for autoimmune diseases. Traditionally used

Silverback Therapeutics announced that it received $85 million in Series C funding, following closely on the heels of a $78.5 million funding round in March